Overview
Metastatic endometrioid carcinoma to the ovary represents a specific subtype of epithelial ovarian cancer (EOC) where the primary tumor originates elsewhere and metastasizes to the ovary. Management strategies for EOC have evolved with new therapeutic agents and biomarker identification, though resistance remains a challenge 1.Diagnosis
Diagnosis relies on histopathological examination of tissue samples 1.
Biomarker identification can aid in selecting patients for targeted therapies 1.Management
Treatment strategies for epithelial ovarian cancer are evolving with new therapeutic agents 1.
Targeted agents are utilized, with biomarker identification helping to select appropriate patients 1.
Resistance to many new agents is common 1.Key Recommendations
New strategies have been incorporated into the therapeutic armamentarium for epithelial ovarian cancer, significantly changing outcomes 1.
Identification of new predictive and prognostic biomarkers enables the selection of patients more likely to respond to targeted agents 1.
Despite advances, epithelial ovarian cancer remains a highly lethal disease, and resistance to many new agents is common 1.References
1 Perez-Fidalgo JA, Gálvez-Montosa F, Guerra EM, Madariaga A, Manzano A, Martin-Lorente C et al.. SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024. link